Cellmid Ltd News Today

/PRNewswire/ -- The "Asia Pacific Alopecia Treatment Market by Product Type, End-Use, and Country-wise Insights: Industry Analysis, Size, Share, Growth,...

Glomerulonephritis Treatment Market by drug class (Corticosteroids, Diuretic, Alkylating Agents) and by distribution channel (Hospital Pharmacies, E-commer

Glomerulonephritis Treatment Market by drug class (Corticosteroids, Diuretic, Alkylating Agents) and by distribution channel (Hospital Pharmacies, E-commer

The Hair Loss Treatment Market is expected to grow at a CAGR of 3.77% and is poised to reach US$XX Billion by 2027 as compared to US$XX Billion in 202

S&P/ASX 200 on track for seventh consecutive month of gains Amazon on Thursday released first-quarter results that exceeded analysts’ expectations, with sales soaring 44% year-over-year to US$108.5 billion and profits more than tripling to US$8.1 billion. Brent crude oil price rose 1.3% to US$68.16 a barrel on Thursday. S&P/ASX 200 (INDEXASX:XJO) dipped 0.60% to 7,039.5 points by 12.51 pm even as US markets rose overnight on strong corporate earnings data. Locally, this is a secon...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

Cellmid receives Chinese import permits for its Jo-Ju® and Lexilis® branded shampoos The health and beauty-tech business is focused on global distribution and sales of its scientifically validated innovative consumer products. The import permits allow the sale of the shampoo products in any channel in mainland China. Cellmid Ltd (ASX:CDY) has received Chinese import permits for its Jo-Ju® and Lexilis® branded shampoos from the National Medical Products Administration (NMPA). Thi...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...

FTSE 100 closes on the front foot, with AstraZeneca the top riser Footsie finished Friday ahead by around eight points, or 0.12%, at 6,969, FTSE 100 closes around eight points higher AstraZeneca top blue-chip riser 5.05pm: FTSE closes ahead FTSE 100 closed on the front foot at the end of the trading week, with drugs giant and much-in-the-news COVID-19 vaccine producer AstraZeneca (LON:AZN) the top dog. Footsie finished ahead by around eight points, or 0.12%, at 6,969, with the psychologically...